• This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Sun - Fri 8:00 - 20:30
The 'Press Releases' section offers the latest product-specific and company-related updates to our esteemed clients, providing them with a valuable resource. Members can leverage this platform for quick, efficient, and effective visibility.

— Our press release programs complement our content distribution initiatives, ensuring strong positioning across major media outlets and social media channels. This enhances the visibility of your message within the global pharmaceutical industry.
ORTHOFX FXCLEAR ALIGNER

FXClear™ Aligners Work Faster and Smarter Than Invisalign®

OrthoFX™, a leader in innovative clear aligner technology, announced preliminary results from a retrospective clinical study comparing treatment effectiveness and predictability of its FXClear aligner system with the leading clear aligner brand, Invisalign. The study, titled "Treatment Effectiveness of FXClear Aligner.

Read more →
Mohit (Mo) Trikha, Ph.D., CEO, Kivu Bioscience

Kivu Bioscience Names Mohit Trikha, Ph.D., CEO

Kivu Bioscience, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for difficult-to-treat cancers, announced the appointment of Mohit Trikha, Ph.D., as Chief Executive Officer. Dr. Trikha, who previously served as President and Chief Operating Officer, assumes the role following the company’s continued progress advancing its pipeline programs ahead of schedule.

Read more →
Nintedanib Capsules

Nintedanib Capsules: Approved and Now Available

Dexcel Pharma USA is pleased to announce that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nintedanib Capsules, 100 mg and 150 mg, the generic equivalent of OFEV® (nintedanib) capsules1. Nintedanib is indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a serious and progressive lung disease. 

Read more →
TECVAYLI

Johnson & Johnson Wins U.S. Food and Drug Administration Approval for TECVAYLI + DARZALEX FASPRO in Relapsed/Refractory Multiple Myeloma

Johnson & Johnson a worldwide leader in multiple myeloma therapies, announced that the U.S. Food and Drug Administration (FDA) approved TECVAYLI® plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.1 TECVAYLI® and DARZALEX FASPRO® work synergistically to prime and activate the immune system to eradicate myeloma cells that express the BCMA protein.

Read more →
Paradise catheter

Otsuka Medical Devices/Otsuka Pharmaceutical announces the commercial launch of the Paradise Ultrasound Renal Denervation System in Japan

Otsuka Medical Devices Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. (Otsuka Pharmaceutical) announce that the Paradise™ Ultrasound Renal Denervation (uRDN) system is covered by National Health Insurance system in Japan, effective March 1. Following the inception of insurance coverage, Otsuka Medical Devices has commenced sales of the system on March 2 and will conduct co-promotion with Otsuka Pharmaceutical.

Read more →